Tuesday, 24 April 2018 - 0:07
  • it
  • de
  • en
  • fr

Zambon

An analysis of Italian multinational Menarini

Milano Finanza has published a long article about the Italy-based multinational Menarini, which has grown at higher rates than the pharmaceutical industry’s average over the last years. The group, controlled by the holding company Pharmafin, which belongs to the Aleotti…

FDA approves Xadago (Zambon) for Parkinson’s treatment

Zambon Group announced today, jointly with Newron Pharmaceuticals and US WorldMeds, that FDA has approved Xadago (safinamide). Xadago is a treatment for Parkinson’s disease which acts as a selective MAO-B inhibitor, in combination with levodopa/carbidopa. The approval has been granted…

Xadago in Australia and New Zealand, Zambon, Seqirus to sign agreement

Zambon and Seqirus announced that they have entered into a long-term partnership covering Xadago (safinamide), Zambon’s product targeting Parkinson’s Disease, in Australia and New Zealand. Zambon will be responsible for product availability, while Seqirus will take charge of product registration…

New Zambon-Fabbrica Italiana Sintetici agreement

Zambon group has announced it has signed an agreement under which Fabbrica Italiana Sintetici (FIS) will take over Zambon’s chemical plant in Lonigo (Vicenza). This transaction creates a strategic partnership between Zambon, operating in the pharmaceutical and chemical field since…

Roberto Tascione takes office as new CEO of Zambon

Roberto Tascione, 54, with a long experience in the pharmaceutical sector, is the new CEO of Zambon SpA, a pharmaceutical company part of Zambon Group. He started his career at Bristol Myers Squibb Italy, with several tasks and responsibilities, then…